GENOCEA BIOSCIENCES, INC.

(GNCA)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
0.0741 USD   -19.46%
05/2524/7 MARKET NEWS : Genocea Biosciences, Inc. (NASDAQ: GNCA) Dead Cat bouncing
AQ
05/25US Futures Move Lower Ahead of Durable Goods, Investor Confidence Reports
MT
05/25Top Premarket Gainers
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GENOCEA BIOSCIENCES, INC. : Entry into a Material Definitive Agreement (form 8-K)

01/04/2022 | 07:05am EDT
Item 1.01 Entry into a Material Definitive Agreement.
On December 28, 2021, Genocea Biosciences, Inc. (the "Company") entered into a
research and development collaboration and option agreement (the "Agreement")
with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical
Companies of Johnson and Johnson, to use the Company's proprietary ATLASTM
platform to explore the immunogenicity of neoantigens and the role and impact of
inhibitory antigens, or InhibigensTM, in the context of vaccine therapies for
cancer. Under the Agreement, the Company will receive an upfront fee of
$1.7 million for research relating to an identified tumor type and is eligible
to receive research and development funding up to a potential total of
$3.3 million. The Agreement includes an option for Janssen to negotiate a future
strategic partnership to develop non-personalized vaccine products relating to
two tumor types using Genocea's ATLAS platform and expertise on Inhibigens.
The foregoing description of the principal terms of the Agreement is a general
description only, does not purport to be complete, and is qualified in its
entirety by reference to the terms of the Agreement, which will be attached as
an exhibit to the Company's next periodic filing.
Item 7.01 Regulation FD Disclosure.
On January 4, 2022, the Company issued a press release announcing the Agreement.
A copy of the press release is attached hereto as Exhibit 99.1. The information
in this Item 7.01 of this Form 8-K, including Exhibit 99.1, is being furnished
and shall not be deemed filed for purposes of Section 18 of the Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that section, nor will it be incorporated by reference in any filing under
the Securities Act or in any filing under the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01  Financial Statements and Exhibits.
(d) Exhibits
99.1        Press release issued by Genocea Biosciences, Inc. on January 4, 2022
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about GENOCEA BIOSCIENCES, INC.
05/2524/7 MARKET NEWS : Genocea Biosciences, Inc. (NASDAQ: GNCA) Dead Cat bouncing
AQ
05/25US Futures Move Lower Ahead of Durable Goods, Investor Confidence Reports
MT
05/25Top Premarket Gainers
MT
05/24Genocea Biosciences To Wind Down Operations; Shares Fall
MT
05/24GENOCEA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
05/24Genocea Announces Wind Down of Operations and Delisting From NASDAQ
AQ
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/29Top Premarket Decliners
MT
04/29HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy
MT
More news
Analyst Recommendations on GENOCEA BIOSCIENCES, INC.
More recommendations